Psychedelic Therapy: A Primer for Primary Care Clinicians-5-Methoxy-N,N-Dimethyltryptamine.
Level 5 - mechanism / opinion, no new human data
Narrative clinical review without systematic search or meta-analytic methodology
PubMed 41714909 · doi:10.1097/MJT.0000000000002106
What was done
This narrative primer summarized the pharmacology, safety profile, and early clinical trial evidence for 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT; mebufotenin) as an ultra-short-acting psychedelic for psychiatric conditions.
What was found
Top-line results from a cited phase 2b trial reported that 57.5% of participants with treatment-resistant depression remitted within 8 days. Other phase 2a and 2b trials indicated symptom reductions greater than standard selective serotonin reuptake inhibitors. However, only 2 double-blind randomized controlled trials have been completed in clinical populations, with existing sample sizes capped at n ≤ 193.
Why it matters
If validated in larger trials, 5-MeO-DMT could provide an ultra-rapid antidepressant option that requires significantly shorter clinical administration sessions than longer-acting psychedelics like psilocybin.
Limits
The underlying evidence base is restricted to small sample sizes (n ≤ 193) and very few randomized controlled trials, with long-term efficacy, durability, and safety remaining uncharacterized. The article itself is an unsystematic narrative overview.
Cited by
- supports 5-MeO-DMT is a naturally occurring compound found in the secretions of the Sonoran Desert toad.